QIAGEN (QGEN)
(Delayed Data from NYSE)
$41.89 USD
+0.67 (1.63%)
Updated Apr 23, 2024 04:00 PM ET
4-Sell of 5 4
C Value F Growth D Momentum F VGM
Income Statements
Fiscal Year end for QIAGEN NV falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1,965 | 2,142 | 2,252 | 1,870 | 1,526 |
Cost Of Goods | 732 | 757 | 801 | 638 | 521 |
Gross Profit | 1,234 | 1,385 | 1,451 | 1,233 | 1,005 |
Selling & Adminstrative & Depr. & Amort Expenses | 824 | 853 | 821 | 846 | 1,031 |
Income After Depreciation & Amortization | 410 | 531 | 630 | 386 | -26 |
Non-Operating Income | 73 | 40 | 50 | 124 | 23 |
Interest Expense | 53 | 58 | 54 | 71 | 74 |
Pretax Income | 430 | 513 | 626 | 439 | -78 |
Income Taxes | 89 | 89 | 113 | 80 | -36 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 341 | 423 | 513 | 359 | -41 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 341 | 423 | 513 | 359 | -41 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 645 | 774 | 877 | 634 | 246 |
Depreciation & Amortization (Cash Flow) | 236 | 242 | 247 | 247 | 272 |
Income After Depreciation & Amortization | 410 | 531 | 630 | 386 | -26 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 230.62 | 223.23 | 225.07 | 227.19 | 225.45 |
Diluted EPS Before Non-Recurring Items | 2.07 | 2.45 | 2.73 | 2.22 | 1.47 |
Diluted Net EPS (GAAP) | 1.48 | 1.90 | 2.28 | 1.58 | -0.19 |
Fiscal Year end for QIAGEN NV falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 509.16 | 475.89 | 494.86 | 485.40 |
Cost Of Goods | NA | 193.06 | 177.93 | 182.71 | 177.92 |
Gross Profit | NA | 316.10 | 297.96 | 312.15 | 307.48 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 205.49 | 200.78 | 206.72 | 210.77 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 110.61 | 97.18 | 105.43 | 96.71 |
Non-Operating Income | NA | 20.70 | 15.67 | 10.38 | 26.53 |
Interest Expense | NA | 12.44 | 13.02 | 13.50 | 14.45 |
Pretax Income | NA | 118.88 | 99.83 | 102.32 | 108.79 |
Income Taxes | NA | 21.21 | 22.01 | 21.53 | 23.75 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 97.66 | 77.82 | 80.79 | 85.04 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 97.66 | 77.82 | 80.79 | 85.04 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 230.75 | 223.70 | 223.60 | 223.68 |
Diluted EPS Before Non-Recurring Items | NA | 0.55 | 0.52 | 0.53 | 0.53 |
Diluted Net EPS (GAAP) | NA | 0.39 | 0.35 | 0.36 | 0.38 |